SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/26/2018 5:05:54 PM - Followers: 133 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
SureTrader
RXII
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4596   Geert, How about having a company that drives BioPharma 01/26/18 05:05:54 PM
#4595   Absolutely CORRECT in my opinion as a long NGIN 01/23/18 01:52:43 PM
#4594   Jan 8, 2018 Bio Showcase Conference presentation: sabaidii2 01/20/18 06:37:34 PM
#4593   RXi is going to run out of cash BioPharma 01/20/18 05:29:10 AM
#4592   This Company and CEO are terrible. First of Inoviorulez 01/16/18 06:55:54 PM
#4591   My money is made generally by this time Full Contact Yoga 01/16/18 02:28:01 PM
#4590   One might wonder why you're even here. You Marksch1 01/16/18 02:17:15 PM
#4589   It's their typical noise. To further dilute, and, Full Contact Yoga 01/16/18 12:42:35 PM
#4588   Why is that hilarious? The Other Guy 01/16/18 11:58:55 AM
#4587   Hilarious...they just provided the script for what they Full Contact Yoga 01/16/18 09:26:27 AM
#4586   Uh... isn't that what all the past conferences/presentations sabaidii2 01/14/18 08:19:58 PM
#4585   $RXII RXi will attend BIO CEO CONFERENCE in BioPharma 01/14/18 01:33:44 PM
#4584   Thanks yep pretty much "smoke and mirrors" IMO NGIN 01/08/18 02:03:19 PM
#4583   Yep. Not too pretty. They Full Contact Yoga 01/08/18 01:59:11 PM
#4582   RXI-109 for dermal scarring will begin Phase 2B sabaidii2 01/08/18 01:37:13 PM
#4581   3rd RS, the actual biz plan is to Full Contact Yoga 01/08/18 11:48:38 AM
#4580   Total debacle...R/S is happening and Geert collects a NGIN 01/08/18 10:54:57 AM
#4579   Couldn't agree More!!! HORRIBLE is an understatement!! NGIN 01/08/18 10:53:13 AM
#4578   Tomorrow is make and break day. BioPharma 01/07/18 03:00:08 PM
#4577   No, it's all part of the perpetual paper Full Contact Yoga 01/06/18 05:38:01 PM
#4576   Is there any chance of RS being cancelled? Stok4life 01/06/18 03:55:29 PM
#4575   Worst biotech CEO I have ever seen. It Inoviorulez 01/05/18 10:11:49 PM
#4574   I TOTALLY AGREE and after a 3rd R/S NGIN 01/05/18 08:50:10 PM
#4573   If it is a failed company, why MirImmune BioPharma 01/05/18 05:42:14 PM
#4572   This company has been epic fail for awhile. Inoviorulez 01/05/18 04:28:47 PM
#4571   Unreal... The Other Guy 01/05/18 02:31:39 PM
#4570   Or, RS Monday, dilute...look for a massive drop Full Contact Yoga 01/05/18 01:36:08 PM
#4569   This I agree with. The concern is not The Other Guy 01/04/18 11:40:58 AM
#4568   RXI's problem is its finances. While I'd prefer sabaidii2 12/31/17 09:38:52 PM
#4567   Seems to have been climbing bit for the Full Contact Yoga 12/29/17 03:59:59 PM
#4566   You Got that right EPIC FAIL!!! NGIN 12/29/17 03:53:06 PM
#4565   Yep, RS right around the corner. Geert Full Contact Yoga 12/19/17 12:54:23 PM
#4564   Correct...Its obvious if WallStreet or Big Money isn't NGIN 12/19/17 10:14:40 AM
#4563   Means nothing...could simply be more toxic notes, debt Full Contact Yoga 12/18/17 11:51:19 PM
#4562   Where is the 7dollars. The hedge funds kept BioPharma 12/18/17 11:32:40 PM
#4561   Today is fact, such positive results made SP BioPharma 12/18/17 11:30:42 PM
#4559   Don’t be naive. The Other Guy 12/18/17 10:28:37 AM
#4558   https://finance.yahoo.com/news/rxi-pharmaceuticals-announces-positive-results-12 Ares_The_Investor 12/18/17 09:59:54 AM
#4557   And you know this how? Please post Full Contact Yoga 12/18/17 09:53:54 AM
#4556   Show us the money RXI The Other Guy 12/18/17 09:27:51 AM
#4555   RXi Pharmaceuticals Announces Positive Results from Phase 2 The Other Guy 12/18/17 09:25:04 AM
#4554   Trial results or scarring trial are in! microchips 12/18/17 07:57:14 AM
#4553   Hedge funds still short this stock, every time BioPharma 12/16/17 08:45:02 PM
#4552   That is why I was looking @ it Work Harder 12/08/17 04:07:46 PM
#4551   15c fluctuating price would be good to trade. The Other Guy 12/08/17 04:02:11 PM
#4550   Took it off the watch list Work Harder 12/08/17 03:39:31 PM
#4549   Doesn’t look bad. Does it? The Other Guy 12/08/17 02:10:58 PM
#4548   Does't look good Work Harder 11/30/17 02:15:33 AM
#4547   They either show the REAL data, good or NGIN 11/29/17 10:42:24 PM
#4546   Once again RXII proves why the market has Inoviorulez 11/29/17 06:40:27 PM
PostSubject